The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some available weight loss solutions, retatrutide appears to offer a greater substantial loss in body size and benefit metabolic health, par